SB
Live / Registered — Registered (as of 06 Oct 2026)
What this means for you
Registered since 06 Oct 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 06 Oct 2032: the §71 affidavit of use).
Record
- Serial number
- 79446759
- Registration number
- 8481364
- Mark type
- Design + words
- Filed
- 22 Oct 2025
- Published for opposition
- 18 Aug 2026
- Registered
- 06 Oct 2026
- Next maintenance filing
- §71 affidavit of use, due by 06 Oct 2032 (grace period to 06 Apr 2033)
- Attorney of record
- Michael T. Smith
Goods and services
- Class 005 — Pharmaceuticals: Diagnostic biomarker reagents for medical purposes; medicines for human purposes, namely, medicines for the treatment of cardiovascular and cerebrovascular diseases, central nervous system stimulants, tumor suppressing agents, diagnostic agents for medical purposes, pharmaceutical agents affecting peripheral nervous system, medicines for intestinal disorders, medicines for dental purposes, medicines for alleviating constipation, medicines for adjusting the menstrual cycle, medicines for the treatment of gastrointestinal diseases, anti-cancer preparations, medicaments for promoting recovery from tendon and muscle injuries and disorders and sports related injuries, blood and immune system diseases, nervous system degenerative and traumatic disorders, metabolic and endocrine system diseases, cardiovascular and retinal degenerative diseases, bone, joint and cartilage injuries, and tumors; immunostimulants; biological preparations for medical purposes, namely, biological preparations for the treatment of cancer, biological preparations for use in cell cultures for medical purposes, stem cells for medical purposes, cells for medical use, biologics in the nature of cells for medical use, antibody reagents used for the detection of antigens in cells and tissue for medical purposes, biological preparations for the treatment of blood and immune system diseases, nervous system degenerative and traumatic disorders, metabolic and endocrine system diseases, cardiovascular and retinal degenerative diseases, bone, joint and cartilage injuries, and tumors; collagen for medical purposes; drugs for medical purposes, namely, the treatment of cancer, blood and immune system diseases, nervous system degenerative and traumatic disorders, metabolic and endocrine system diseases, cardiovascular and retinal degenerative diseases, bone, joint and cartilage injuries, and tumors; enzymes for medical purposes; enzyme preparations for medical purposes; pharmaceutical preparations, namely, anti-epileptic pharmaceutical preparations, cardiovascular pharmaceutical preparations, pharmaceutical preparations for treating hypertension, pharmaceutical preparations for treating diabetes, pharmaceutical preparations for suppressing tumors, pharmaceutical preparations for peripheral nervous system, pharmaceutical preparations for the central nervous system, pharmaceutical preparations used in organ transplantation, pharmaceutical preparations for the treatment of musculo-skeletal disorders; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; pharmaceutical preparations for cellular therapy for the treatment of blood and immune system diseases, nervous system degenerative and traumatic disorders, metabolic and endocrine system diseases, cardiovascular and retinal degenerative diseases, bone, joint and cartilage injuries, and tumors; organotherapy preparations; nutraceutical preparations for use as a dietary supplement for therapeutic or medical purposes; vaccines; stem cells for veterinary purposes; transplants, being implants comprised of living tissues; blood plasma; hair serums for medical purposes; skin serums for medical purposes; lip serums for medical purposes; biological tissue cultures for veterinary purposes; medicines for veterinary purposes, namely, medicines for the treatment of cancer, stem cells for veterinary purposes
- Class 042 — Scientific and technological services: Chemical research; product quality testing; scientific research in the nature of conducting clinical trials for others; medical research laboratory services; medical research; stem cell research services; biological cloning services; biological research; genetic testing for scientific research purposes; bacteriological research
- Class 044 — Medical, beauty and agricultural services: Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical clinic services; convalescent home services; services of a psychologist; rental of sanitary installations; stem cell therapy services; cognitive therapy services; meditation therapy services; nutritional therapy services; speech pathology therapy services; hormone replacement therapy services; intravenous (IV) hydration therapy services; bodywork therapy services, namely, craniosacral, acupressure, massage, structural integration and movement therapy; physical therapy services for the treatment of blood and immune system diseases, nervous system degenerative and traumatic disorders, metabolic and endocrine system diseases, cardiovascular and retinal degenerative diseases, bone, joint and cartilage injuries, and tumors; telemedicine services; massage; health care consultancy; health counseling
Owner
Prosecution history
- 06 Oct 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 06 Oct 2026 — REGISTERED-PRINCIPAL REGISTER
- 18 Aug 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 18 Aug 2026 — PUBLISHED FOR OPPOSITION
- 12 Aug 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Jul 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 Jul 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 13 Jul 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 13 Jul 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 04 Jun 2026 — REFUSAL PROCESSED BY IB
- 15 May 2026 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 14 May 2026 — REFUSAL PROCESSED BY MPU
- 29 Mar 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 28 Mar 2026 — NON-FINAL ACTION WRITTEN
- 28 Mar 2026 — ASSIGNED TO EXAMINER